SETTLEMENT AND TERMINATION AGREEMENTSettlement & Termination Agreement • November 9th, 2023 • BeiGene, Ltd. • Pharmaceutical preparations • New York
Contract Type FiledNovember 9th, 2023 Company Industry JurisdictionThis SETTLEMENT AND TERMINATION AGREEMENT (this “Agreement”), dated as of August 1, 2023 (the “Effective Date”), is entered into by and among Bristol-Myers Squibb Company, a Delaware corporation (“BMS”), Celgene Corporation, a Delaware corporation (“Celgene Corporation”), Celgene Switzerland LLC, a Delaware limited liability company (“Celgene Switzerland”), Celgene Holdings East Corporation, a New Jersey corporation (“Celgene East”), Celgene Kappa Holdings LLC, a Delaware limited liability company (“Celgene Kappa”) and Celgene Logistics Sàrl (“Celgene Logistics”), a corporation incorporated under the laws of Switzerland, on the one hand (collectively, with BMS, Celgene Corporation, Celgene Switzerland, Celgene East, Celgene Kappa and Celgene Logistics, “Celgene”), and BeiGene, Ltd., an exempted company incorporated under the laws of the Cayman Islands, and BeiGene Switzerland GmbH, a company incorporated in Switzerland (“BeiGene Switzerland”, and together with BeiGene, Ltd., “BeiGene”)
MUTUAL TERMINATION AND RELEASE AGREEMENTMutual Termination and Release Agreement • November 9th, 2023 • BeiGene, Ltd. • Pharmaceutical preparations • New York
Contract Type FiledNovember 9th, 2023 Company Industry JurisdictionThis MUTUAL TERMINATION AND RELEASE AGREEMENT (this “Agreement”), dated as of September 17, 2023, is entered into by and between Novartis Pharma AG, a Swiss corporation (“Novartis”) and BeiGene Switzerland GmbH, a Swiss corporation (“BeiGene”). Each of Novartis and BeiGene may be referred to herein as a “Party” and collectively as the “Parties.”